Active Substance: glycopyrronium bromide
Common Name: glycopyrronium bromide
ATC Code: R03BB06
Marketing Authorisation Holder: Novartis Europharm Ltd.
Active Substance: glycopyrronium bromide
Authorisation Date: 2012-09-28
Therapeutic Area: Pulmonary Disease, Chronic Obstructive
Pharmacotherapeutic Group: Drugs for obstructive airway diseases
Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
What is Tovanor Breezhaler and what is it used for?
Tovanor Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Tovanor Breezhaler is used for maintenance (regular) treatment.
Tovanor Breezhaler contains the active substance glycopyrronium bromide.
How is Tovanor Breezhaler used?
Tovanor Breezhaler capsules, which contain a powder for inhalation, are only used with the Tovanor Breezhaler inhaler and must not be swallowed. To take a dose, the patient places a capsule into the inhaler and breathes in through the mouth the powder from the capsule. For detailed information on how to use the inhaler correctly, see the instructions in the package leaflet.
The recommended dose is one capsule once a day at the same time each day. Patients should not use more than one capsule in a day.
Tovanor Breezhaler can only be obtained with a prescription.
How does Tovanor Breezhaler work?
The active substance in Tovanor Breezhaler, glycopyrronium bromide, is a muscarinic receptor antagonist. This means that it widens the airways by blocking muscarinic receptors (targets) in muscle cells in the lungs. Muscarinic receptors control the contraction of muscles and when glycopyrronium bromide is inhaled, it relaxes the muscles of the airways. This helps to keep the airways open and allows the patient to breathe more easily.
What benefits of Tovanor Breezhaler have been shown in studies?
Tovanor Breezhaler was found to be more effective than placebo (a dummy treatment) at relieving symptoms of COPD in two main studies involving a total of 1,888 patients with COPD. In both studies, the main measure of effectiveness was improvement in patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).
After 12 weeks of treatment, Tovanor Breezhaler increased FEV1 by 97 ml more than with placebo in the first study, and by 108 ml more in the second study.
What are the risks associated with Tovanor Breezhaler?
The most common side effects with Tovanor Breezhaler (seen in more than 1 patient in 100) are dry mouth, nasopharyngitis (inflammation of the nose and throat), insomnia (difficulty sleeping), muscle and bone pain and gastroenteritis (diarrhoea and vomiting). For the full list of all side effects and restrictions with Tovanor Breezhaler, see the package leaflet.
Why is Tovanor Breezhaler approved?
The Agency noted that Tovanor Breezhaler had a modest but relevant benefit for patients in terms of improving lung function, and also improved the symptoms of COPD. The Agency also noted that the fact that the medicine is used once a day may help patients to adhere to their treatment. In addition, there were no major safety concerns with Tovanor Breezhaler, with side effects similar to other muscarinic receptor antagonist medicines. Therefore, the Agency decided that Tovanor Breezhaler’s benefits are greater than its risks and recommended that it be given marketing authorisation.
What measures are being taken to ensure the safe and effective use of Tovanor Breezhaler?
As muscarinic receptor antagonist medicines may have an effect on the heart and blood vessels, the company that markets Tovanor Breezhaler will continue to closely monitor the medicine’s cardiovascular effects and will carry out a further study in patients to identify any potential risks.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tovanor Breezhaler have also been included in the summary of product characteristics and the package leaflet.
Other information about Tovanor Breezhaler
The European Commission granted a marketing authorisation valid throughout the European Union for Tovanor Breezhaler on 28 September 2012.
For more information about treatment with Tovanor Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.